{"transactions":[{"id":713321,"issuer":{"id":7345,"kind":"organization","name":"Scilex Holding Co"},"owners":[{"id":31611,"kind":"organization","name":"SCLX Stock Acquisition JV LLC","position":1,"cik":"0001994894","reported_name":"SCLX Stock Acquisition JV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2026-07-08T01:25:20.000Z","date":"2026-07-03","kind":"other","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 3, 2026, the Reporting Person entered into a letter agreement (the \"Letter Agreement\") with Quantum Scan Holdings, Inc. (\"Q Scan\") and the other party named therein, pursuant to which the Reporting Person transferred the shares reported herein to Q Scan in exchange for shares of common stock of Q Scan. The price at which the shares reported herein are being transferred to Q Scan will be based on the closing price of the shares of Scilex common stock on the Nasdaq Capital Market on the last trading day immediately prior to the transfer of such shares pursuant to the Letter Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 3, 2026, the Reporting Person entered into a letter agreement (the \"Letter Agreement\") with Quantum Scan Holdings, Inc. (\"Q Scan\") and the other party named therein, pursuant to which the Reporting Person transferred the shares reported herein to Q Scan in exchange for shares of common stock of Q Scan. The price at which the shares reported herein are being transferred to Q Scan will be based on the closing price of the shares of Scilex common stock on the Nasdaq Capital Market on the last trading day immediately prior to the transfer of such shares pursuant to the Letter Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares beneficially owned reflects the 1-for-35 reverse stock split effected April 15, 2025."}],"balance_after":958263,"source":{"system":"sec-edgar","filing":"0001193125-26-297858","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1820190/000119312526297858/ownership.xml","form_type":"4"}},{"id":1296116,"issuer":{"id":7345,"kind":"organization","name":"Scilex Holding Co"},"owners":[{"id":31611,"kind":"organization","name":"SCLX Stock Acquisition JV LLC","position":1,"cik":"0001994894","reported_name":"SCLX Stock Acquisition JV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-01-24T00:49:49.000Z","date":"2025-01-21","kind":"other","planned":false,"acquired":false,"shares":3250000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transferred pursuant to the terms of an Amendment to Senior Secured Promissory Note (the \"Amendment Letter\") the Issuer and the Reporting Person entered into with Oramed Pharmaceuticals Inc. (\"Oramed\") for the extension of the maturity date of that certain senior secured promissory note previously issued by the Issuer to Oramed on September 21, 2023. Under the terms of the Amendment Letter and in consideration for such extension and to limit certain noteholders' rights to exercise certain secured creditor remedies (including recourse against the assets of the Reporting Person as a grantor under the Security Agreement (as defined in the Amendment Letter)), the Reporting Person transferred to Oramed an aggregate of 3,250,000 shares of common stock, par value $0.0001 per share of the Issuer, held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Transferred pursuant to the terms of an Amendment to Senior Secured Promissory Note (the \"Amendment Letter\") the Issuer and the Reporting Person entered into with Oramed Pharmaceuticals Inc. (\"Oramed\") for the extension of the maturity date of that certain senior secured promissory note previously issued by the Issuer to Oramed on September 21, 2023. Under the terms of the Amendment Letter and in consideration for such extension and to limit certain noteholders' rights to exercise certain secured creditor remedies (including recourse against the assets of the Reporting Person as a grantor under the Security Agreement (as defined in the Amendment Letter)), the Reporting Person transferred to Oramed an aggregate of 3,250,000 shares of common stock, par value $0.0001 per share of the Issuer, held by the Reporting Person."}],"balance_after":51039214,"source":{"system":"sec-edgar","filing":"0000950170-25-008463","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1820190/000095017025008463/ownership.xml","form_type":"4"}},{"id":1299571,"issuer":{"id":7345,"kind":"organization","name":"Scilex Holding Co"},"owners":[{"id":31611,"kind":"organization","name":"SCLX Stock Acquisition JV LLC","position":1,"cik":"0001994894","reported_name":"SCLX Stock Acquisition JV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-01-18T01:27:54.000Z","date":"2025-01-16","kind":"other","planned":false,"acquired":false,"shares":779371,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transferred in connection with a First Amendment to License and Commercialization Agreement (the \"License Amendment\") the Issuer entered into with Rxomeg Therapeutics, LLC a/k/a Romeg Therapeutics, LLC (\"Romeg\"), as contemplated by that certain Transfer Agreement entered into between the Issuer and Romeg (the \"Transfer Agreement\"). In consideration of the execution of the License Amendment and the Transfer Agreement, the Reporting Person transferred to Romeg an aggregate of 779,371 shares of common stock, par value $0.0001 per share of the Issuer, held by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Transferred in connection with a First Amendment to License and Commercialization Agreement (the \"License Amendment\") the Issuer entered into with Rxomeg Therapeutics, LLC a/k/a Romeg Therapeutics, LLC (\"Romeg\"), as contemplated by that certain Transfer Agreement entered into between the Issuer and Romeg (the \"Transfer Agreement\"). In consideration of the execution of the License Amendment and the Transfer Agreement, the Reporting Person transferred to Romeg an aggregate of 779,371 shares of common stock, par value $0.0001 per share of the Issuer, held by the Reporting Person."}],"balance_after":54289214,"source":{"system":"sec-edgar","filing":"0000950170-25-006876","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1820190/000095017025006876/ownership.xml","form_type":"4"}},{"id":1309520,"issuer":{"id":7345,"kind":"organization","name":"Scilex Holding Co"},"owners":[{"id":31611,"kind":"organization","name":"SCLX Stock Acquisition JV LLC","position":1,"cik":"0001994894","reported_name":"SCLX Stock Acquisition JV LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-01-07T00:12:44.000Z","date":"2025-01-02","kind":"other","planned":false,"acquired":false,"shares":5000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transferred pursuant to the terms of a Deferral and Consent Letter (collectively, the \"Consent Letters\") the Issuer and the Reporting Person entered into with each of (i) Nomis Bay Ltd and BPY Limited, (ii) Oramed Pharmaceuticals Inc. (\"Oramed\") and (iii) 3i, LP, respectively (collectively, the \"Noteholders\") for the deferral of certain amortization payments owned by the Issuer to the Noteholders. Under the terms of the Consent Letters and in consideration for such deferrals and to limit the Noteholders' right to exercise certain secured creditor remedies (including recourse against the assets of the Reporting Person as a grantor under the Security Agreement (as defined in the Consent Letters)),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) the Reporting Person transferred to the Noteholders an aggregate of 5,000,000 shares of common stock, par value $0.0001 per share of the Issuer, held by the Reporting Person, of which 2,500,000 shares were delivered to Oramed, 720,000 shares were delivered to BPY Limited, 1,280,000 shares were delivered to Nomis Bay Ltd, and 500,000 shares were delivered to 3i, LP."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Transferred pursuant to the terms of a Deferral and Consent Letter (collectively, the \"Consent Letters\") the Issuer and the Reporting Person entered into with each of (i) Nomis Bay Ltd and BPY Limited, (ii) Oramed Pharmaceuticals Inc. (\"Oramed\") and (iii) 3i, LP, respectively (collectively, the \"Noteholders\") for the deferral of certain amortization payments owned by the Issuer to the Noteholders. Under the terms of the Consent Letters and in consideration for such deferrals and to limit the Noteholders' right to exercise certain secured creditor remedies (including recourse against the assets of the Reporting Person as a grantor under the Security Agreement (as defined in the Consent Letters)),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) the Reporting Person transferred to the Noteholders an aggregate of 5,000,000 shares of common stock, par value $0.0001 per share of the Issuer, held by the Reporting Person, of which 2,500,000 shares were delivered to Oramed, 720,000 shares were delivered to BPY Limited, 1,280,000 shares were delivered to Nomis Bay Ltd, and 500,000 shares were delivered to 3i, LP."}],"balance_after":55068585,"source":{"system":"sec-edgar","filing":"0000950170-25-002437","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1820190/000095017025002437/ownership.xml","form_type":"4"}}]}